RedHill Biopharma Ltd. announced the appointment of Dr. June S. Almenoff, M.D., Ph.D., FACP, as Chief Scientific Officer. Dr. Almenoff, an accomplished pharma executive with extensive gastroenterology and infectious diseases expertise, will lead the Company’s commercial strategy as it relates to medical and scientific matters, including the medical affairs activities for Talicia® (RHB-105)1 in preparation for potential U.S. commercial launch in the fourth quarter of 2019. In addition, Dr. Almenoff will oversee the clinical development of RHB-204 for pulmonary nontuberculous mycobacteria (NTM) infections and the pivotal Phase 3 study planned to be initiated in the second half of 2019. With over 20 years of experience in the pharmaceutical industry, Dr. Almenoff served in various roles, including the President and Chief Medical Officer of Furiex Pharmaceuticals. Prior to joining Furiex, Dr. Almenoff worked at GlaxoSmithKline plc (GSK), where she held various positions of increasing responsibility. She has recently served as a board member and advisor to numerous biopharma companies.